- Vivity is the most implanted extended depth of focus (EDOF)
intraocular lens (IOL) globally1
- Milestone underscores the impact of Vivity’s
first-of-its-kind, patented wavefront-shaping technology, which
simplifies presbyopia correction for surgeons and
patients2,3
- Vivity demonstrates excellent outcomes, with real-world
Vivity Registry data from more than 900 cataract patients,
including patients with certain mild comorbidities as well as
post-refractive eyes4
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated
to helping people see brilliantly, today proudly announces AcrySof®
IQ Vivity® and Clareon® Vivity extended depth of focus (EDOF)
intraocular lenses (IOLs) have surpassed more than one million
implants worldwide. Vivity is the most implanted EDOF IOL
globally.1* Alcon is the global leader in IOLs—every four seconds
an eye is implanted with an Alcon IOL—and continues to innovate in
this space to address patients’ unmet needs.5
“We are proud to celebrate the one million Vivity eyes
empowering cataract patients to see the world with high quality
vision from distance to functional near—day and night,” said Sean
Clark, President, Global Surgical Franchise at Alcon. “This
milestone embodies our commitment to addressing the diverse vision
needs of today's patients, who desire less dependence on glasses
post-surgery and low visual disturbances, with a game-changing
presbyopia-correcting intraocular lens (PCIOL) option that expands
the patient candidacy pool.”
Vivity uses Alcon’s patented non-diffractive Wavefront-Shaping
X-WAVE™ technology, an advanced optical principle that
simultaneously stretches and shifts light without splitting
it—balancing quality of vision and maximizing range of vision.2,3
The optic delivers excellent distance and intermediate vision, as
well as functional near vision.2 The unique mechanism of action is
not refractive, does not introduce spherical aberrations and has
ultimately expanded PCIOL access to even more patients. Vivity is
designed to simplify presbyopia correction, prioritizing patient
satisfaction while minimizing surgeon and clinic chair time.
Recent, large-scale real-world data underscores the impact of
Vivity on patients across the globe. The Vivity Registry Study4+
includes patients with common mild comorbidities like glaucoma, dry
eye and retinopathy/maculopathy, as well as post-refractive eyes.
The Registry data demonstrates high patient satisfaction among
several patient cohorts, as the vast majority of patients (92%)
report they are satisfied with their sight.∞ Additionally, more
than 91% of patients report no haloes, glares, or starbursts.†
Vivity is available in more than 80 countries, including
Australia, Brazil, Canada, China, France, Germany, Japan, India,
Italy, Russia, South Korea, Spain, U.K. and U.S. Alcon offers a
family of leading IOLs designed to meet the unique vision needs of
patients, including Vivity and PanOptix®—the most implanted PCIOLs
worldwide—as well as monofocal and toric options. PanOptix
surpassed one million implants in early 2022, and is the most
implanted trifocal worldwide.5,6 For more information, please visit
www.ClareonIOL.com.
About Vivity
The non-diffractive Clareon® Vivity® Extended Vision Hydrophobic
Posterior Chamber IOLs (referred to as Clareon® Vivity®) and
AcrySof® IQ Vivity® Extended Vision Posterior Chamber Intraocular
Lens Model DFT015 (referred to as AcrySof® IQ Vivity® IOL) are
UV-absorbing and blue-light-filtering foldable intraocular lenses
(IOLs). Vivity® IOL provides an extended range of vision from
distance to near, with low levels of visual disturbances.
Potential side effects: As with any surgery, there is an
implicit risk, whether or not the IOL is implanted. The
complications of the IOL implantation surgery ranges from minor
side effects (usually temporary) to serious complications. Patients
with previous illnesses or disorders (such as chronic infections of
the eye or eyelids, or diabetes) may present a higher risk of
complications. Temporary surgical complications include, but are
not limited to, reactions to medications such as irritation or mild
allergic response, bleeding, redness, itching of the eye,
sensitivity to light, swelling, corneal edema (swelling of the
cornea), problems with the iris, cell growth in the IOL, and an
increase temporary eye pressure. There is a small risk of needing
further surgical treatment after the implantation of the initial
IOL.
About PanOptix
The AcrySof® IQ PanOptix® Trifocal IOL and the Clareon®
PanOptix® Trifocal IOL are types of multifocal IOLs used to focus
images clearly onto the back of your eye (retina) to allow clear
vision after the cataract removal. In addition, the center of the
PanOptix® Trifocal IOL allows for better near (reading) vision and
intermediate (computer work) vision versus what a monofocal lens
would provide.
Potential side effects: Due to the design of multifocal IOLs,
there are some side effects that can be associated with the
AcrySof® IQ and Clareon® PanOptix® Trifocal IOL models. These may
be worse than with a monofocal IOL, including visual disturbances,
such as glare, rings around lights, starbursts (rays around light
sources), and reduced contrast sensitivity (decrease in ability to
distinguish objects from their background, especially in dim
lighting). These side effects may make it more difficult to see
while driving at night or completing tasks in low lighting
conditions such as at night or in fog or in a dimly lit room after
surgery as compared to before surgery.
Further, a toric IOL corrects astigmatism only when it is placed
in the correct position in the eye. There is a possibility that the
toric IOL could be placed incorrectly or could move within the eye.
If the toric lens is not positioned correctly following surgery,
the change in your astigmatism correction by the IOL, along with
any necessary correction with glasses, may cause visual
distortions. If the lens rotates in your eye, you may need
additional surgery to reposition or replace the IOL.
About Alcon
Alcon helps people see brilliantly. As the global leader in eye
care with a heritage spanning over 75 years, we offer the broadest
portfolio of products to enhance sight and improve people’s lives.
Our Surgical and Vision Care products touch the lives of more than
260 million people in over 140 countries each year living with
conditions like cataracts, glaucoma, retinal diseases and
refractive errors. Our more than 25,000 associates are enhancing
the quality of life through innovative products, partnerships with
Eye Care Professionals and programs that advance access to quality
eye care. Learn more at www.alcon.com.
References
- Market Scope - 2023 Premium Cataract Surgery Market Report;
2023 IOL Market Report.
- Alcon Data on File; U.S. Pat. Nos. RE45,969, 9,968,440,
11,083,566.
- AcrySof® IQ Vivity® or Clareon® Vivity® IOL Directions for
Use.
- Reus NJ, Kooijman M, Perez-Vives C. Overall Visual Outcomes
from a Real-world Study of Presbyopia-correcting IOLs in a Large
Population. Presented at the European Society of Cataract and
Refractive Surgery (ESCRS) Annual Meeting; 8-12 Sept. 2023; Vienna,
Austria.
- Alcon Data on File, 2024. REF-22137.
- Alcon IOL Global Sales; Jan. 2021-Nov. 2022.
*Based on independent market audit - Market Scope - 2023 Premium
Cataract Surgery Market Report. +The Vivity® Registry Study was a
multicentre, ambispective, non-comparative, open-label,
non-interventional registry study conducted across 41 sites from
eight (8) countries: Australia, Belgium, Germany, New Zealand, the
Netherlands, Portugal, Spain and the United Kingdom. ∞Subject
satisfaction was evaluated with the Catquest 9SF Questionnaire.
Statistic refers to ‘very’ or ‘fairly’ satisfied. †Visual
disturbances were evaluated by asking open, non-prompted questions
about visual experience.
Connect with us on Facebook LinkedIn
©2024 Alcon Inc. 03/24 GLB-VIV-2400001
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240305584198/en/
Media Relations Steven Smith
+41 589 112 111 (Geneva) +1 817 551 8057 (Fort Worth)
globalmedia.relations@alcon.com
Alcon (NYSE:ALC)
Historical Stock Chart
From Jul 2024 to Aug 2024
Alcon (NYSE:ALC)
Historical Stock Chart
From Aug 2023 to Aug 2024